Moderna announced that it will be charging between #32 to $37 per dose for their vaccine candidate for some customers. The company described this as "pandemic pricing."
This announcement came as Moderna reported earnings on Wednesday.
Revenue was up to $66.4 million during the quarter, and it reported $13.1 million in the same period last year.
Moderna reported a second-quarter loss of $116.7 million, or 31 cents a share.
“The second quarter marked a new growth phase for as we started to build our commercial team, a historic moment for those of us who have worked at the company for many years since it was a breakthrough research enterprise. We would like to thank the entire team for their commitment to our mission of delivering on a new class of medicines for patients,” said Stéphane Bance, Moderna’s Chief Executive Officer. “In the second quarter, we began discussions with several countries for supply agreements for mRNA-1273 and as of, we have received approximately of customer deposits for potential supply. As we pivot to a commercial-stage company, we recognize the need for responsible pricing in the face of the pandemic. We look forward to continuing our progress as we prepare for the Phase 3 readout and the expected subsequent filing of our BLA.”
More on Vaccines: Jim Cramer: Novavax Is in the Running for a COVID-19 Vaccine
Latest Videos From TheStreet and Jim Cramer:
- Coronavirus Update: CVS and Activision Blizzard Report Earnings
- Why Is TikTok So Valuable? Jim Cramer Explains
- Who Has the Power to Delay the Presidential Election?
- When You'll Find Clorox Wipes on Shelves
- Ask Bob: How To Fix Excess IRA Contributions
- Movies You Won't Be Seeing in 2020